Kiyatec Inc., of Greenville, S.C., an SCRA Technology Ventures company, said it received a Fast Track Phase I and Phase II Small Business Innovation Research contract for $1.725 million from the National Cancer Institute. The goal is to develop culture systems that can grow and maintain the rare population of cancer stem cells, which are believed to lead to therapy resistance, relapse and death from metastatic disease. Kiyatec's focus is small-cell lung cancer.